300356-14-3

Upstream product

• 588940-80-1 (2R)-2-[3-chloro-4-(methylsulfanyl)phenyl]-3-cyclopentylpropanoic acid 
• 87776-75-8 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid 
• 1265819-83-7 (3-Chloro-4-methanesulfonyl-phenyl)acetic acid 
• 1265819-87-1 (E)-2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid Sodium Salt 
• 1265819-85-9 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid dicyclohexylamine salt 
• 345635-33-8 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid 
• 1265819-90-6 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid, dicyclohexylamine salt 
• 1266162-63-3 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid acid sodium salt 
• 17733-22-1 2-chlorothioanisole 
• 393165-02-1 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester 
• 588940-69-6 (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide 

Downstream Products

• 710321-35-0 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-methanesulfonylamino-pyridin-2-yl)-propionamide 
• 300354-12-5 N-(5-bromo-pyridin-2-yl)-2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionamide 
• 300354-11-4 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-pyridin-2-yl-propionamide 
• 436141-85-4 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-quinolin-2-yl-propionamide 
• 588941-45-1 RO 0505082 
• 588941-33-7 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(2-oxo-1,2-dihydro-pyrimidin-4-yl)-propionamide 
• 588941-05-3 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-pyrimidin-4-yl-propionamide 
• 710321-27-0 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-methylsulfanyl-pyrazin-2-yl)-propionamide 
• 710322-16-0 N-(5-bromo-pyrazin-2-yl)-2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionamide 
• 710321-93-0 2(R)-(3-chloro-methanesulfonyl-phenyl)-3-cyclopentyl-N-[5-(3-methoxy-phenyl)-pyrazin-2-yl]-propionamide 
• 710321-36-1 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-methanesulfonylamino-pyrazin-2-yl)-propionamide 
• 710321-44-1 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-dimethoxymethyl-pyrazin-2-yl)-propionamide 
• 710322-32-0 N-[5-(1-tert-butoxyimino-ethyl)-pyrazin-2-yl]-2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionamide 
• 710322-35-3 5-[2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionylamino]-pyrazine-2-carboxylic acid tertbutyl ester 

Relevant academic research and scientific papers

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES

The present invention relates to a process for the preparation of (R)-2-phenyl propionic acid derivatives of the formula wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen, or of a salt thereof.

PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES

The present invention relates to a process for the preparation of (R)-2-phenyl propionic acid derivatives of the formula (I) wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen, or of a salt thereof. (R)-2-phenyl propio

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

Fused heteroaromatic glucokinase activators

Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.